Clinical Trial

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-07.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT07123415
Lead Sponsor Aptabio Therapeutics, Inc.
Conditions Advanced Solid Cancer, Advanced Solid Tumor (Phase 1)
Enrollment 110 participants
Start Date 2025-10-24
Primary Completion 2028-10 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-19